Literature DB >> 7076216

IgA nephropathy: morphologic predictors of progressive renal disease.

S M Lee, V M Rao, W A Franklin, M S Schiffer, A J Aronson, B H Spargo, A I Katz.   

Abstract

IgA nephropathy has a variable course and leads to renal failure in a substantial number of cases. In an attempt to identify prognostic indicators in this disease, we evaluated the clinical and pathologic findings of 20 unselected patients with IgA nephropathy, 13 of whom were followed for 1.5 to 5 years (mean 2.8 years). Biopsy specimens were obtained from all patients and were examined by light and electron microscopy and by immunofluorescence. The activity and severity of the lesions were graded according to a modified classification used by Meadow et al. for the nephropathy associated with Henoch-Schönlein purpura. The results reveal a correlation between the histopathologic grading in the initial biopsy and the clinical outcome: Patients with mild (grade II) or moderate (grade III) lesions had a benign course or showed evidence of active disease without deterioration of renal function, whereas all patients with grade IV or V lesions who were followed for more than one year developed end-stage renal failure. These observations suggest that histologic grading at initial renal biopsy may be a useful prognostic indicator of the clinical outcome of IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076216     DOI: 10.1016/s0046-8177(82)80221-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  72 in total

1.  Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy.

Authors:  L-L Liu; Y Jiang; L-N Wang; N Liu
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Authors:  Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

3.  Long-term follow up of renal function in IgA nephropathy.

Authors:  U B Berg
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

4.  The use of the Oxford classification of IgA nephropathy to predict renal survival.

Authors:  Eric Alamartine; Catherine Sauron; Blandine Laurent; Aurore Sury; Aline Seffert; Christophe Mariat
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

5.  IgA nephropathy in adults: immunohistologic findings and clinical course.

Authors:  S K Parai; T Ghose
Journal:  Can Med Assoc J       Date:  1985-06-15       Impact factor: 8.262

6.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Treatment of IgA nephropathy of adults presented by nephrotic syndrome.

Authors:  Senija Rasić; Snjezana Uncanin; Kenana Aganović; Ismar Rasić; Jasminka Dzemidzić; Alma Muslimović
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

8.  Quantitative study of mesangial injury with proteinuria induced by monoclonal antibody 1-22-3.

Authors:  H Kawachi; T Oite; F Shimizu
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Histopathologic features aid in predicting risk for progression of IgA nephropathy.

Authors:  Michael Walsh; Aylin Sar; Diane Lee; Serdar Yilmaz; Hallgrimur Benediktsson; Braden Manns; Brenda Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

10.  alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.

Authors:  Mara Ferrandi; Daniele Cusi; Isabella Molinari; Lucia Del Vecchio; Cristina Barlassina; Maria Pia Rastaldi; Francesco Paolo Schena; Fabio Macciardi; Carmelita Marcantoni; Dario Roccatello; Luanne L Peters; Silvia Armelloni; Li Min; Laura Giardino; Deborah Mattinzoli; Claudio Camisasca; Fiorentina Palazzo; Paolo Manunta; Patrizia Ferrari; Giuseppe Bianchi
Journal:  J Mol Med (Berl)       Date:  2009-10-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.